Trial
NCT03093272
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Dana-Farber Cancer Institute
Collaborators
Janssen Pharmaceuticals
Condition
Prostate Cancer
Intervention
Leuprolide Acetate
Why stopped
Safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-09